



PATENT PC9674BJTJ

JAN 06 2003

TECH CENTER 1600/2900

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: William J. Curatolo, et al.

SERIAL NO.: 09/770,562

FILED: January 26, 2001

FOR: Solid Pharmaceutical Dispersions
With Enhanced Bioavailability

: Examiner: B. Fubara

: Art Unit: 1615

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as First Class Mail in an
envelope addressed to: Assistant Commissioner
for Patents, Washington, D.C. 20231 onAssistant Commissioner For Patents
Washington, D.C. 20231this 16th day of December 2002

Sir:

AMENDMENT TRANSMITTAL

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2) Claims Remaining After Amendment	(3)	(4) Highest Number Previously Paid For	(5) Present Extra	(6) Rate	Additional Fee
Total Claims	81*	minus	38**	= 43	X \$18.00	774.00
Independent Claims	8*	minus	5***	= 3	X \$84.00	249.00
	<input type="checkbox"/> Multiple Dependent Claim(s) fee				\$280.00	

* If the entry in column 2 is less than the entry in column 4, write "0" in column 5.

** If the "Highest No. Previously Paid for" is less than 20, write "20" in this space.

*** If the "Highest No. Previously Paid for" is less than 3, write "3" in this space.

- A Petition for Extension of Time for responding within one (1) month(s) of the response date is also enclosed. Authorization to charge the fee transfer is made separately therein.
- No additional fee is required.
- Please charge Deposit Account No. 16-1445 in the amount of \$1,023.00. Two copies of this paper are enclosed.

AMENDMENT

- The Commissioner is hereby authorized to charge any additional fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Respectfully submitted,

Date: Dec. 16, 2002

James T. Jones
James T. Jones
Attorney for Applicant(s)
Reg. No. 30,561

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 441-4903

RECEIVED

JAN 06 2003

TECH CENTER 3/600/2900

PATENT PC9674B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: William J. Curatolo, et al.

SERIAL NO.: 09/770,562

FILED: January 26, 2001

FOR: Solid Pharmaceutical Dispersions
With Enhanced Bioavailability

Assistant Commissioner For Patents
Washington, D.C. 20231

: Examiner: B. Fubara
: Art Unit: 1615

: I hereby certify that this correspondence
is being deposited with the United States
Postal Service as First Class Mail in an
envelope addressed to: Assistant Commissioner
for Patents, Washington, D.C. 20231 on

12-16-02

this 16th day of December 20 02

By _____

Response Under Rule 111

Bet
1-8-03

Please enter

1/9/03 BR

Sir:

This is in response to the FINAL Office Action dated June 18, 2002, the term
for response having been extended three (3) months by including the appropriate fee
and petition herewith.

In response to the Office Action, entry of the following changes in the
application is respectfully requested:

In the claims:

1. (Twice Amended) A composition comprising a spray dried solid
dispersion, which dispersion comprises a sparingly water-soluble drug having a dose
to aqueous solubility ratio greater than 100 mL and hydroxypropylmethylcellulose
acetate succinate (HPMCAS), said dispersion providing a maximum concentration of
said drug in a use environment that is higher by a factor of at least 1.5 relative to a
control composition comprising an equivalent quantity of undispersed drug.

Cancel claim 2.

Cancel claim 3.

1. (Twice Amended) A composition of matter comprising a spray-dried solid
dispersion, which dispersion comprises a sparingly water-soluble drug having a dose
to aqueous solubility ratio greater than 100 mL and HPMCAS, said dispersion
exhibiting a maximum supersaturated concentration in MFD solution which is higher
by a factor of at least 1.5 relative to the equilibrium concentration exhibited by a
control composition comprising an equivalent quantity of undispersed drug.

09770562

00000053 161445

774.00 CH
252.00 CH

01/02/2003 JAD001

03 FC1202
04 FC1201